Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations

Darcy Kerr, Hector U. Lopez, Vikram Deshpande, Francis J. Hornicek, Zhenfeng Duan, Yaxia Zhang, Andrew Rosenberg, Darrel R. Borger, G. Petur Nielsen

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Distinguishing chondrosarcoma from chondroblastic osteosarcoma can be difficult and highly subjective, especially on a small biopsy specimen. This distinction is critical in determining the most accurate prognosis and appropriate treatment modality, as adjuvant chemotherapy with surgery is standard treatment for osteosarcoma, whereas chondrosarcoma is generally treated by surgical excision alone. Cartilaginous neoplasms have recently been shown to frequently (56%) harbor gene mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2 (IDH1>IDH2), whereas other mesenchymal tumors lack these genetic aberrations. We investigated whether the presence of IDH1/2 mutations can be used to distinguish chondrosarcoma from chondroblastic osteosarcoma. Tumors including 25 predominantly high-grade chondrosarcomas and 65 osteosarcomas (44 chondroblastic osteosarcomas and 21 mixed osteosarcomas with a chondroblastic component) were evaluated, and a total of 59 cases (66%) were suitable for genotyping. Mutational analysis was performed using a multiplexed polymerase chain reaction genotyping platform to query for hotspot mutations in the genes IDH1 at codon R132. IDH1-negative cases underwent Sanger sequencing of IDH2 exon 4. No osteosarcomas (0/36) and 61% of chondrosarcomas (14/23) harbored a somatic mutation in IDH1/2, with the majority (86%) of mutations found in the IDH1 gene. IDH1/2 mutation analysis appears to be a promising biomarker for the distinction of chondrosarcoma from chondroblastic osteosarcoma. A positive result strongly favors the diagnosis of chondrosarcoma over chondroblastic osteosarcoma. The presence of IDH1/2 mutations can also help confirm the diagnosis of dedifferentiated chondrosarcoma when the tumor displays osteosarcomatous differentiation.

Original languageEnglish
Pages (from-to)787-795
Number of pages9
JournalAmerican Journal of Surgical Pathology
Volume37
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Isocitrate Dehydrogenase
Chondrosarcoma
Osteosarcoma
Mutation
Neoplasms
Genes
Adjuvant Chemotherapy
Codon
Exons
Biomarkers
Biopsy
Polymerase Chain Reaction

Keywords

  • Chondrosarcoma
  • Dedifferentiation
  • IDH1
  • IDH2
  • Osteosarcoma

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. / Kerr, Darcy; Lopez, Hector U.; Deshpande, Vikram; Hornicek, Francis J.; Duan, Zhenfeng; Zhang, Yaxia; Rosenberg, Andrew; Borger, Darrel R.; Nielsen, G. Petur.

In: American Journal of Surgical Pathology, Vol. 37, No. 6, 01.06.2013, p. 787-795.

Research output: Contribution to journalArticle

Kerr, Darcy ; Lopez, Hector U. ; Deshpande, Vikram ; Hornicek, Francis J. ; Duan, Zhenfeng ; Zhang, Yaxia ; Rosenberg, Andrew ; Borger, Darrel R. ; Nielsen, G. Petur. / Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. In: American Journal of Surgical Pathology. 2013 ; Vol. 37, No. 6. pp. 787-795.
@article{f923db50ad674746b63fb964b874edd1,
title = "Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations",
abstract = "Distinguishing chondrosarcoma from chondroblastic osteosarcoma can be difficult and highly subjective, especially on a small biopsy specimen. This distinction is critical in determining the most accurate prognosis and appropriate treatment modality, as adjuvant chemotherapy with surgery is standard treatment for osteosarcoma, whereas chondrosarcoma is generally treated by surgical excision alone. Cartilaginous neoplasms have recently been shown to frequently (56{\%}) harbor gene mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2 (IDH1>IDH2), whereas other mesenchymal tumors lack these genetic aberrations. We investigated whether the presence of IDH1/2 mutations can be used to distinguish chondrosarcoma from chondroblastic osteosarcoma. Tumors including 25 predominantly high-grade chondrosarcomas and 65 osteosarcomas (44 chondroblastic osteosarcomas and 21 mixed osteosarcomas with a chondroblastic component) were evaluated, and a total of 59 cases (66{\%}) were suitable for genotyping. Mutational analysis was performed using a multiplexed polymerase chain reaction genotyping platform to query for hotspot mutations in the genes IDH1 at codon R132. IDH1-negative cases underwent Sanger sequencing of IDH2 exon 4. No osteosarcomas (0/36) and 61{\%} of chondrosarcomas (14/23) harbored a somatic mutation in IDH1/2, with the majority (86{\%}) of mutations found in the IDH1 gene. IDH1/2 mutation analysis appears to be a promising biomarker for the distinction of chondrosarcoma from chondroblastic osteosarcoma. A positive result strongly favors the diagnosis of chondrosarcoma over chondroblastic osteosarcoma. The presence of IDH1/2 mutations can also help confirm the diagnosis of dedifferentiated chondrosarcoma when the tumor displays osteosarcomatous differentiation.",
keywords = "Chondrosarcoma, Dedifferentiation, IDH1, IDH2, Osteosarcoma",
author = "Darcy Kerr and Lopez, {Hector U.} and Vikram Deshpande and Hornicek, {Francis J.} and Zhenfeng Duan and Yaxia Zhang and Andrew Rosenberg and Borger, {Darrel R.} and Nielsen, {G. Petur}",
year = "2013",
month = "6",
day = "1",
doi = "10.1097/PAS.0b013e31827ab703",
language = "English",
volume = "37",
pages = "787--795",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations

AU - Kerr, Darcy

AU - Lopez, Hector U.

AU - Deshpande, Vikram

AU - Hornicek, Francis J.

AU - Duan, Zhenfeng

AU - Zhang, Yaxia

AU - Rosenberg, Andrew

AU - Borger, Darrel R.

AU - Nielsen, G. Petur

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Distinguishing chondrosarcoma from chondroblastic osteosarcoma can be difficult and highly subjective, especially on a small biopsy specimen. This distinction is critical in determining the most accurate prognosis and appropriate treatment modality, as adjuvant chemotherapy with surgery is standard treatment for osteosarcoma, whereas chondrosarcoma is generally treated by surgical excision alone. Cartilaginous neoplasms have recently been shown to frequently (56%) harbor gene mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2 (IDH1>IDH2), whereas other mesenchymal tumors lack these genetic aberrations. We investigated whether the presence of IDH1/2 mutations can be used to distinguish chondrosarcoma from chondroblastic osteosarcoma. Tumors including 25 predominantly high-grade chondrosarcomas and 65 osteosarcomas (44 chondroblastic osteosarcomas and 21 mixed osteosarcomas with a chondroblastic component) were evaluated, and a total of 59 cases (66%) were suitable for genotyping. Mutational analysis was performed using a multiplexed polymerase chain reaction genotyping platform to query for hotspot mutations in the genes IDH1 at codon R132. IDH1-negative cases underwent Sanger sequencing of IDH2 exon 4. No osteosarcomas (0/36) and 61% of chondrosarcomas (14/23) harbored a somatic mutation in IDH1/2, with the majority (86%) of mutations found in the IDH1 gene. IDH1/2 mutation analysis appears to be a promising biomarker for the distinction of chondrosarcoma from chondroblastic osteosarcoma. A positive result strongly favors the diagnosis of chondrosarcoma over chondroblastic osteosarcoma. The presence of IDH1/2 mutations can also help confirm the diagnosis of dedifferentiated chondrosarcoma when the tumor displays osteosarcomatous differentiation.

AB - Distinguishing chondrosarcoma from chondroblastic osteosarcoma can be difficult and highly subjective, especially on a small biopsy specimen. This distinction is critical in determining the most accurate prognosis and appropriate treatment modality, as adjuvant chemotherapy with surgery is standard treatment for osteosarcoma, whereas chondrosarcoma is generally treated by surgical excision alone. Cartilaginous neoplasms have recently been shown to frequently (56%) harbor gene mutations in the metabolic enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2 (IDH1>IDH2), whereas other mesenchymal tumors lack these genetic aberrations. We investigated whether the presence of IDH1/2 mutations can be used to distinguish chondrosarcoma from chondroblastic osteosarcoma. Tumors including 25 predominantly high-grade chondrosarcomas and 65 osteosarcomas (44 chondroblastic osteosarcomas and 21 mixed osteosarcomas with a chondroblastic component) were evaluated, and a total of 59 cases (66%) were suitable for genotyping. Mutational analysis was performed using a multiplexed polymerase chain reaction genotyping platform to query for hotspot mutations in the genes IDH1 at codon R132. IDH1-negative cases underwent Sanger sequencing of IDH2 exon 4. No osteosarcomas (0/36) and 61% of chondrosarcomas (14/23) harbored a somatic mutation in IDH1/2, with the majority (86%) of mutations found in the IDH1 gene. IDH1/2 mutation analysis appears to be a promising biomarker for the distinction of chondrosarcoma from chondroblastic osteosarcoma. A positive result strongly favors the diagnosis of chondrosarcoma over chondroblastic osteosarcoma. The presence of IDH1/2 mutations can also help confirm the diagnosis of dedifferentiated chondrosarcoma when the tumor displays osteosarcomatous differentiation.

KW - Chondrosarcoma

KW - Dedifferentiation

KW - IDH1

KW - IDH2

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84880161059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880161059&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e31827ab703

DO - 10.1097/PAS.0b013e31827ab703

M3 - Article

C2 - 23598960

AN - SCOPUS:84880161059

VL - 37

SP - 787

EP - 795

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 6

ER -